

Montana's Opioid Settlements

The United States is in the **midst of a crisis** on its streets and in its communities as **overdoses, homelessness, and disorder reach record levels**. Yet settlement proceeds secured by the State of Montana present an **unprecedented opportunity for generational investment** in treatment capacity for chronic substance abuse (CSA) and severe mental illness (SMI).

Montana is set to receive **more than \$160 million** (\$163,337,865.16) in opioid settlement funds—equal to nearly one-fourth of the state's share of the monumental Tobacco Master Settlement Agreement.¹ With twenty-one separate settlements and payments spread out over decades, the funds are **at risk of being squandered** through ad-hoc allocations to **diffuse and disorganized efforts**.

The state must ensure that this opportunity for treatment investment is not underutilized. **Montana can make targeted investments in treatment capacity** that will **honor those who suffered** in the opioid crisis and **ensure accessible care** for decades to come.

Montana reserves 15 percent of funds for the state's use, allocates 70 percent of funds to an abatement fund (combined total: \$136,931,126.86), and the remainder is allocated to subdivisions.² The state's 15-percent share is split evenly between the Department of Health and Human Services and the Department of Justice, with each Department determining the best uses of funds.³ The abatement funds are held in a trust, managed by a 10-person advisory committee named the Operating Trustees.⁴ The Trustees are vested ultimate allocation authority pursuant to the trust declaration. Comprehensive reports for either the state's uses of funds or the Trust's uses of funds could not be found, making oversight difficult. **The state should enact an allocation statute and vest ultimate allocation authority of the abatement's share of funds in the legislature.**

The state must rein in the potential misallocation of these funds and prioritize investments in comprehensive treatment networks. **Three priorities** (Certified Community Behavioral Health

¹ With the exception of the McKinsey and Publicis settlements, in which the state controls 100 percent of funds. Mallinckrodt and Endo settlements are divided between a non-regional appropriation of 30 percent to the state and a regional appropriation of 70 percent to regional entities.

Clinics, secure psychiatric beds, and community SMI/CSA response) **will ensure these funds have the largest impact** on Montana.

Certified Community Behavioral Health Clinics (CCBHCs)

CCBHCs, designed to ensure access to coordinated comprehensive behavioral health care, have stable funding and are supported by all recent presidential administrations. CCBHCs are a key response to the opioid crisis and can augment other services such as police crisis response teams, homelessness outreach and services, and outpatient psychiatric commitment services.

- **Solution: Fund the development and expansion of CCBHCs.**
 - o Expand the CCBHC footprint with an emphasis on a team-based approach to co-occurring disorders.
 - o Create a stepped approach to SMI/CSA treatment with services provided by the CCBHCs.
 - o Require CCBHCs to offer specific care pathways to meet the needs of individuals with co-occurring disorders.

State Psychiatric Hospitals

Inpatient beds in secure facilities are critical for serving the highest-acuity psychiatric patients. Montana currently has only **10.6 state psychiatric beds** per 100,000 people available for civil (i.e., non-criminal) patients.^{5,6} Treatment Advocacy Center recommends a rate of 30-60 beds per 100,000. Even counting non-public secure psychiatric beds, Montana just reaches the minimum.⁷ Secure beds are a costly but necessary expenditure to protect patients with severe psychiatric disorders and the public at large.

- **Solution: Fund the expansion of civil psychiatric beds.**
 - o Invest in expanding state hospital capacity.
 - o Move forensic (criminal) commitments to a jail-based restoration facility.
 - o Apply for one of several Section 1115(a) waivers to expand Medicaid reimbursement for institutions for mental diseases (IMDs).

Inpatient Stabilization Centers and Mobile Crisis Teams

Emergency departments (EDs) are supposed to be a last resort for times of true emergencies, but are increasingly used for all types of immediate-need medical care. This is especially true for low- to medium-acuity mental health crises. In order for CCBHCs and state psychiatric bed expansions to have the largest impact, there must be an immediate triage of low-acuity patients from higher-need patients, or else investments in these facilities will be drowned out,

overburdened, and underutilized by those that need them most, just like emergency departments.

- **Solution: Fund community-based mental health response resources.**
 - o Expand community-based recovery centers, including voluntary short-term respite housing, especially for young adults.
 - o Leverage CCBHC resources to develop comprehensive mobile crisis response teams in conjunction with police crisis intervention teams (CIT).
 - o Support integration of community resources with crisis networks such as Lifeline to support those in need or provide guidance for concerned loved ones.

MONTANA

[Download all Montana opioid settlement documents](#)

[View settlement fund dashboard](#)

STATE-CONTROLLED FUNDS	ALL FUNDS	2025 EOY FUNDS RECEIVED - STATE	2025 EOY FUNDS RECEIVED - ALL	Av. Receipt (All Funds) / Yr (*20)
\$136,931,126.86	\$163,337,865.16	\$46,500,529.20	\$54,052,122.20	\$8,166,893.26

2021 National Opioid Settlement

Montana v. Distributors

- [Final Consent Judgment](#)
 - [Exhibit A "Distributor Settlement Agreement"](#)
 - [Exhibit B "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
- State of Montana v. McKesson Corporation, et al., Lewis and Clark County First District Court, Case No. DV--2020-0000131

Montana v. Janssen

- [Final Consent Judgment](#)
 - [Exhibit A "Janssen Settlement Agreement"](#)
 - Exhibit A "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding" [p. 13]
- State of Montana v. Johnson & Johnson, et al., Lewis and Clark County First District Court, Case No. ADV2022-637 (DV-2022-0000637)

2022 National Opioid Settlement

Montana v. CVS

- [Final Consent Judgment](#)
 - [Exhibit A "agreement dated as of December 9 2022"](#)
 - [Exhibit 1 "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
 - [Exhibit 2 "Amendment to Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
- State of Montana v. CVS Pharmacy, Inc et al., Lewis and Clark County First District Court, Case No. DV-2023-0000728

Montana v. Walgreens

- [Final Consent Judgment](#)
 - [Exhibit A "agreement dated as of December 9 2022"](#)
 - [Exhibit 1 "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
 - [Exhibit 2 "Amendment to Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)

- State of Montana v. CVS Pharmacy, Inc et al., Lewis and Clark County First District Court, Case No. DV-2023-0000728

Montana v. Walmart

- [Final Consent Judgment](#)
 - [Exhibit A "agreement dated as of November 14 2022"](#)
 - [Exhibit 1 "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
 - [Exhibit 2 "Amendment to Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
- State of Montana v. CVS Pharmacy, Inc et al., Lewis and Clark County First District Court, Case No. DV-2023-0000728

Montana v. Allergan

- [Final Consent Judgment](#)
 - [Exhibit A "Allergan Public Global Opioid Settlement Agreement"](#)
 - [Exhibit B "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
 - [Exhibit C "Amendment to Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
- State of Montana v. Allergan Limited et al., Lewis and Clark County First District Court, Case No. DV-2023-0000727

Montana v. Teva

- [Final Consent Judgment](#)
 - [Exhibit 1 "Teva Global Opioid Settlement Agreement"](#)
 - [Exhibit 2 "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
 - [Exhibit 3 "Amendment to Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
- State of Montana v. Allergan Limited et al., Lewis and Clark County First District Court, Case No. DV-2023-0000727

Other Coalition Opioid Settlements

Montana v. Kroger

- [Final Consent Judgment](#)
 - [Exhibit A "agreement dated as of March 22 2024"](#)
 - [Exhibit 1 "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
 - [Exhibit 2 "Amendment to Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding"](#)
- State of Montana v. The Kroger Co., Lewis and Clark First District Court, Case No. DV-2024-0000792 (DV-25-2024-0000792-OC)

Montana v. McKinsey

- [Final Consent Judgment](#)
- [McKinsey Allocation Amounts](#)
- State of Montana v. McKinsey & Company, Inc. United States, Lewis and Clark First District Court, Case No. DV-2021-0000107 (DDV 2021-107)

Montana v. Mallinckrodt

- [NOAT II Agreement](#)
- [GPM Notice](#)
- [Notice of Abatement Distribution](#)

Montana v. Publicis

- [Final Consent Judgment](#)
 - [Exhibit A “Publicis Multistate Settlement Allocation”](#)
 - [Exhibit B “Publicis Multistate Settlement Allocation of Costs”](#)
- State of Montana vs. Publicis Health, LLC, Lewis and Clark First District Court, Case No. DV-2024-0000074 (BDV-25-2024-0000074-MT)

Montana v. Endo

- [Global Public Trust Agreement](#)
- [Notice of Abatement Distribution](#)

2025 National Settlements

Montana v. Purdue

- [missing documentation]
- State of Montana v. Purdue Pharma L.P., et al., Lewis & Clark County, Case No. ADV-2017-949 [unconfirmed]

Montana v. Mylan

- [missing documentation]

Montana v. Hikma

- [missing documentation]

Montana v. Amneal

- [missing documentation]

Montana v. Apotex

- [missing documentation]

Montana v. Indivior

- [missing documentation]

Montana v. Sun Pharmaceuticals

- [missing documentation]

Montana v. Alvogen

- [missing documentation]

Montana v. Zydus

- [missing documentation]

Independent Settlements

¹ KFF. "Actual Tobacco Settlement Payments Received by the States (in millions)." Accessed 8 September 2025.

<https://www.kff.org/health-costs/state-indicator/tobacco-settlement-payments>.

² "Montana Distributors' and Janssen Opioids Settlement Memorandum of Understanding." <https://drive.google.com/file/d/1-H8opxs74tkD1LUPTdQQvHuFHmT8tbif/view?usp=sharing>.

³ "Montana Department of Public Health and Human Services/Montana Department of Justice Memorandum of Understanding: Allocation and Use of Opioid Settlement Funds." <https://drive.google.com/file/d/1-1sycSRMa6bpY6WsuIlZOPNT0Dtiz5M9/view?usp=sharing>.

⁴ "Declaration of Trust – The Montana Opioid Abatement Trust." <https://montanaopioid.org/wp-content/uploads/2023/10/Opioid-Declaration-of-Trust.pdf>.

⁵ Treatment Advocacy Center. "Montana Psychiatric Beds Report." 2023. <https://www.tac.org/wp-content/uploads/2023/10/Montanabedsinformation.pdf>.

⁶ United States Census Bureau, "2023 American Community Survey – Total Population."

[https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US\\$0400000](https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US$0400000).

⁷ Silver, Shanti, "Estimating Psychiatric Bed Need in the United States," p. 2-4. Treatment Advocacy Center Office of Research and Public Affairs. January 2024. https://www.tac.org/wp-content/uploads/2024/03/TAC_ORPA_ResearchSummary1.24.pdf.